NAMS Should I Buy

RBC Capital raised the firm's price target on NewAmsterdam Pharma to $51 from $47 and keeps an Outperform rating on the shares. The firm's patient survey suggests strong unmet need in LDL-lowering therapies and supports a favorable positioning for obicetrapib as a potential second-line option, with expectations that successful PREVAIL outcomes showing 20% MACE reduction could expand its addressable population and support revised peak revenue estimates of about $2.4B by 2035, the analyst tells investors in a research note.